Severity
Moderate
ModerateActive
CPSC recall · Reported December 18, 2025
Plantimex Recalls Mamisan Lidocaine Ointment Containers Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child-Resistant Packaging
The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, p…
Compiled from official public sources by the editorial team.
Verify with CPSC →
MiramarLab, of Doral, Florida recalled This recall involves Mamisan Pain Relieving Topical Ointment jars. The ointment comes in … - a moderate-severity action.
Plantimex Recalls Mamisan Lidocaine Ointment Containers Due to Risk of Serious Injury or … was recalled by MiramarLab, of Doral, Florida in December 18, 2025. Reason: The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Preven…. Remedy: Consumers should immediately secure the recalled ointment jars out of the sight and reach…. Verify recall #26157 with the CPSC before acting.
The recall
MiramarLab, of Doral, Florida issued this moderate-severity CPSC recall-The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Preven….
- Moderate
- severity level
- December 18, 2025
- reported
Sourced from official CPSC enforcement records. Verify recall #26157 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
Recall Insight
This CPSC action (record #26157) was formally reported on December 18, 2025. It is classified under Moderate severity, with a current status of Active. MiramarLab, of Doral, Florida is listed as the recalling firm. Federal records list the affected scope as About 50,330.
The documented reason for this recall is: The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death … Distribution information was not included in the agency filing, so consumers should assume broad potential exposure until the firm publishes point-of-sale details. The remedy documented by the agency is: Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to receive a free replacement lid. Once the product is secured with the rep… - consumers holding this product should act on that instruction rather than relying on general guidance.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Drugs & Medications recalls over time
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Affected scope
About 50,330
Related Recalls
6
0 from same agency
Product description
This recall involves Mamisan Pain Relieving Topical Ointment jars. The ointment comes in an orange container with a white continuous thread lid and has the Mamisan trademark printed on top of the lid and on the label. The ointment was sold in a 3.52 ounce plastic jar. The wraparound label includes instructions and drug facts. Only jars with UPC code 860006498115 are included in the recall.
Reason for recall
The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.
Remedy, what to do
Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to receive a free replacement lid. Once the product is secured with the replacement lid, consumers can use the product, as directed.
Recall Profile
| Attribute | Value |
|---|---|
| Agency | U.S. Consumer Product Safety Commission |
| Severity class | Moderate |
| Status | Active |
| Recall number | 26157 |
| Date reported | December 18, 2025 |
| Date initiated | December 18, 2025 |
| Recalling firm | MiramarLab, of Doral, Florida |
| Affected scope | About 50,330 |
| Distribution | Not disclosed |
| Official source | CPSC notice → |
Profile values are sourced directly from the official CPSC enforcement record. Source: U.S. Consumer Product Safety Commission.
What to do with this recall
Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to re…
- Check the recall number (26157) and product description against the item you own. Search the archive
- Confirm the current status and remedy on the official CPSC notice before acting. CPSC notice
- Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next
This page summarizes the official CPSC record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Frequently Asked Questions
What product was recalled? ▼
This recall involves Mamisan Pain Relieving Topical Ointment jars. The ointment comes in an orange container with a white continuous thread lid and has the Mamisan trademark printed on top of the lid and on the label. The ointment was sold in a 3.52 ounce plastic jar. The wraparound label includes instructions and drug facts. Only jars with UPC code 860006498115 are included in the recall.. Recalled by MiramarLab, of Doral, Florida. Units affected: About 50,330.
Why was this product recalled? ▼
The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.
What should consumers do? ▼
Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to receive a free replacement lid. Once the product is secured with the replacement lid, consumers can use the product, as directed.
Which agency issued this recall? ▼
This recall was issued by the CPSC on December 18, 2025. Severity: Moderate. Recall number: 26157.
How do I check if my product is affected by a recall? ▼
Check the product description and recall number (26157) against your product. Visit the official CPSC website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
How do I report an injury from a recalled product? ▼
Report injuries to the issuing agency: CPSC at SaferProducts.gov, NHTSA at nhtsa.gov/report-a-safety-problem, or FDA via MedWatch. Document the product (photos, model/serial numbers, purchase receipts) and seek medical attention. Injury reports help agencies track hazard patterns and may strengthen enforcement actions.
Nearby Recalls in This Category
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
FDA Drug Low
PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie c…
AbbVie Inc. · 2026-06-03
FDA Food Moderate
Vitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement, Net Wt. 8 FL Oz (237mL) Amber PET modern round 24-400 bot…
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
FDA Drug Moderate
Atomoxetine Capsules HCL, 10 mg Capsules in unit dose foil strip, strips are packed in cartons of 100, Rx Only, Pkg by:…
Safecor Health, LLC · 2026-05-27
FDA Drug Moderate
fentaNYL Citrate, Sterile CADD for Injection, 2,2500 mcg/50mL in Sterile Water, IntegraDose Compounding Services LLC, 3…
IntegraDose Compounding Services LLC · 2026-05-27
FDA Drug Moderate
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, …
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: CPSC, reported December 18, 2025. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.